Verdict: Side-by-side breakdown using the Bull Rankings model. BNTX scored 28.0, HRMY scored 88.5 — HRMY leads.
Compare another set
BNTX
BioNTech SE
Biotechnology · Quality-Growth
28
$96.96 · $24.4B
fundamentals as of
Score gap
60.5
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
Biotechnology · Quality-Growth
88.5
$40.28 · $2.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthHRMY+24.3%
Strongest balance sheetBNTX0.02
Highest qualityHRMY79 / 100
Largest discount to fair valueHRMY-71%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
BNTX
stronger →← stronger
HRMY
35
Qualityreturns · margins · balance sheet
79
44
Growthrevenue & earnings expansion
95
17
Valuevaluation vs sector peers
92
HRMY is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
BNTX
HRMY
$499mC
FCF
$355mC
+4.3%C+
Rev
+24.3%A-
0.02A-
D/E
0.16B+
8.2xC+
P/S
—
0.05A
PEG
0.38A
—
P/E
13.0xA
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BNTX
HRMY
160% above
Price vs fair valuelower is cheaper
71% below
~41%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-15%/yr
-70%
1-yr DCF upside
+168%
-62%
5-yr DCF upside
+249%
-46%
10-yr DCF upside
+413%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BNTX
Why this score
Diluting shareholders
Foreign reporter (EUR)
HRMY
Why this score
Durable high returns
The companies
BNTXBioNTech SE
Biotechnology · $96.96 · beta 1.25
Why now
Biotechnology · market cap $24.4b. Down 22% from 52-week high of $124.00 — deep drawdown territory. PEG 0.05 — paying under fair value for the growth rate. 20 sell-side analysts rate this a Buy with a mean 1-yr target of $116.21 (implying +20% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -63.6%) — path to GAAP profitability is the core thesis risk. ROE -9% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
HRMYHarmony Biosciences Holdings, Inc.
Biotechnology · $40.28 · beta 1.01
Why now
Biotechnology · market cap $2.3b. 7% off the 52-week high of $43.49. Revenue growing +24%, comfortably above the S&P median. PEG 0.38 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $47.64 (implying +18% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BNTX and HRMY diverge
On the headline score the gap is 60.5 points in favor of HRMY. The widest single difference is Value, where HRMY leads by 75.5 points.
ValueBNTX 16.7 · HRMY 92.2HRMY +75.5
GrowthBNTX 43.8 · HRMY 94.5HRMY +50.7
QualityBNTX 35.0 · HRMY 79.5HRMY +44.5
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is HRMY or BNTX the better stock?
HRMY scores higher: HRMY 88.5, BNTX 28.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do HRMY and BNTX differ most?
The widest gap is value, where HRMY leads by 76 points on the 0–100 pillar scale. HRMY leads all three pillars, so the gap is broad rather than a single-measure difference.
How are HRMY and BNTX scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.